Peptide services/genscript/drew deniger
Ended Awarded
- Contract number
- HHSN26100103
- Awardee
-
Genscript USA Inc. UEI KVLBRRAQ6UX1
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,969
Award facts
- Opportunity
-
- N02RC5256683 Solicitation number
- Detection of mutation-reactive T cells in patients with metastatic cancers Award Notice · Posted Apr 14, 2015
- Contract value 100% obligated
- $4,968.71 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 621511 Medical Laboratories
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Bethesda, MD 20892, USA
Award details come from SAM.gov/FPDS.
Quick answers
Who was awarded contract HHSN26100103?
HHSN26100103 was awarded to Genscript USA Inc. by National Cancer Institute (National Institutes of Health) on February 18, 2016.
How much is contract HHSN26100103 worth?
The government has obligated $4,969 on HHSN26100103.
Is contract HHSN26100103 an order under another contract?
Yes. HHSN26100103 is a delivery order under HHSN261201500015I, an indefinite delivery contract.
Was contract HHSN26100103 competed?
The extent of competition for HHSN26100103 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award